Prophylactic and therapeutic HSV-specific mAbs prevent nHSV-associated mortality . Abs were delivered intraperitonially to pregnant dams, or pups. Pups were challenged intranasally 2 d post-partum with indicated viral dose, then observed to DPI 21. (A) Survival of pups following administration of CH42 (red, dam n = 2, two litters, pup n = 9) or IgG control (ctrl, black, dam n = 2, two litters, pup n = 11) to B6 background pregnant dams 5 d before infection. (B) Survival of B6 pups following administration of E317 (blue, one litter, n = 6) or IgG control (black, one litter, n = 4) 1 d before infection in solid lines. Survival of a single litter for which one half received CH42 (red, n = 4) and the other half IgG control (black, n = 4) 1 d postinfection in dashed lines. (C) Survival of pups following HSV8 (purple, one litter, n = 8), UB-621 (teal, one litter, n = 6), CH42 (red, one litter, n = 6), or IgG control (black, two litters, n = 17) administration immediately before infection with HSV-1. Survival of pups following HSV8 (purple, two litters, n = 11), UB-621 (teal, one litter, n = 9), CH42 (red, one litter, n = 9), or IgG control (black, two litters, n = 11) administration immediately before infection with HSV-2. Statistical significance was determined by the Log-rank (Mantel-Cox) test; HSV-specific mAbs are compared to IgG control (ctrl). *, P < 0.05; **, P < 0.01; ***, P < 0.001. DPI, day postinfection.